Novonesis consensus picture on Tuesday, shares tracked in Copenhagen and Frankfurt
26.06.2026 - 13:49:50 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 13:49.
Novonesis (DK0060336014) starts the week with its B shares actively quoted on Nasdaq Copenhagen and on German platforms such as Tradegate. The stock sits in the wider Nordic life-sciences universe alongside peers Novo Nordisk and Chr. Hansen, with investors watching earnings expectations and valuation metrics according to MarketScreener data.MarketScreener consensus overview
What analysts currently expect
For Novonesis, aggregated analyst data compiled by MarketScreener show a limited but concrete consensus on revenue and earnings for the current fiscal year, with estimates in Danish kroner and a focus on the enzyme and biosolutions franchise.MarketScreener consensus overview The name is typically covered by Nordic brokerages that also track Novo Nordisk and other life-sciences names, which helps investors compare growth and margins across the sector.
According to consensus snapshots on financial portals such as Finanzen100, Novonesis B shares trade with a price level in the mid-50-euro range on German trading venues when converted from Danish kroner, giving the company a mid-cap valuation in European healthcare terms.Finanzen100 price overview for Novonesis B The valuation is often compared with other enzyme and biosolutions players, taking into account the transition from the former Novozymes structure.
Novonesis in the wider sector context
Within the broader life-sciences and biosolutions space, investors also look at large-cap peers such as Novo Nordisk, which recently attracted fresh analyst attention when Goldman Sachs raised its price target to 310 Danish kroner while keeping a Neutral stance.MarketScreener Novo Nordisk broker updates This type of coverage provides a benchmark for how growth, profitability and capital allocation in the Nordic healthcare ecosystem are rewarded.
The enzyme and biosolutions niche in which Novonesis operates is also being highlighted by market research, including reports that see the biostimulants market, where microbial and enzyme-based solutions play a role, reaching around 8.77 billion US dollars by 2031.Finanzen100 reference to biostimulants market report Such sector projections feed into long-term growth assumptions in analyst models for companies like Novonesis.
All news and analysis on the Novonesis shares
Key figures, consensus data and further corporate news on Novonesis can be found in the dedicated topic area and on the company’s investor-relations pages.
How Novonesis makes its money
Novonesis generates its revenue primarily from industrial enzymes and biosolutions that are used in food and beverages, household care, bioenergy and agriculture. Product families include enzyme blends for baking and brewing, detergents that improve cleaning performance at lower temperatures, and microbial solutions that enhance crop resilience and yield in sustainable farming systems.
Where the shares trade today
The Novonesis B shares (DK0060336014) most recently changed hands on Tradegate at 54.13 euros on 2026-06-26, 13:30, reflecting the euro-quoted line for the Danish biosolutions group alongside its primary Nasdaq Copenhagen listing.
Key data on the Novonesis shares
- Company: Novonesis A/S
- ISIN: DK0060336014
- WKN: A1JP9Y
- Ticker: NZM2
- Trading venue: Tradegate
- Price (as of 2026-06-26, 13:30): 54.13 EUR
- Market cap: 15.0 billion EUR (as of 2026-06-26)
- Sector / industry: Biotechnology / Enzymes and biosolutions
- Index membership: OMX Copenhagen benchmark index
- Next earnings date: 2026-08-08
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on publicly available sources and may change without notice.
